- Despite flunking a Phase 2 trial for its diabetic macular edema asset (KVD001), KalVista Pharmaceuticals' stock has remained steady, except for a brief coronavirus related plunge.
- Investors are more focused on the results of a KVD900 Phase 2 trial for patients with hereditary angioedema, which, after a year of delays, looks poised to produce data soon.
- With KVD900's potential game-changing oral delivery and recent insider buying, KalVista merited another look.
- A full investment analysis follows in the paragraphs below.
For further details see:
KalVista Pharmaceuticals: Caution Warranted